• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?静脉注射皮质类固醇冲击是否优于小剂量皮质类固醇治疗重症 COVID-19 患者?
Eur Respir J. 2022 Oct 20;60(4). doi: 10.1183/13993003.01220-2022. Print 2022 Oct.
2
Methylprednisolone therapy induces differential metabolic trajectories in severe COVID-19 patients.甲泼尼龙治疗诱导重症 COVID-19 患者产生不同的代谢轨迹。
mSystems. 2023 Dec 21;8(6):e0072623. doi: 10.1128/msystems.00726-23. Epub 2023 Oct 24.
3
Predicting the response to methylprednisolone pulses in patients with SARS-COV-2 infection.预测 SARS-CoV-2 感染患者对甲基强的松龙脉冲治疗的反应。
Med Clin (Barc). 2022 Dec 23;159(12):557-562. doi: 10.1016/j.medcli.2022.02.025. Epub 2022 Jun 17.
4
Corticosteroids May Be Indicated in Children with Severe COVID-19 Disease.对于患有重症新冠疾病的儿童,可能需要使用皮质类固醇。
Pediatr Ann. 2021 Jul;50(7):e270-e271. doi: 10.3928/19382359-20210701-01. Epub 2021 Jul 1.
5
Reply: Corticosteroids May Be Indicated in Children with Severe COVID-19 Disease.回复:对于患有重症新冠疾病的儿童,可能需要使用皮质类固醇。
Pediatr Ann. 2021 Jul;50(7):e271. doi: 10.3928/19382359-20210520-01. Epub 2021 Jul 1.
6
Corticosteroid Protection Against COVID-19: Begin with the Nose.皮质类固醇对新冠病毒的防护:从鼻腔开始。
J Allergy Clin Immunol Pract. 2021 Nov;9(11):3941-3943. doi: 10.1016/j.jaip.2021.08.025. Epub 2021 Sep 17.
7
COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence.COVID-19 风险和结局在接受生物制剂或全身皮质类固醇治疗的成年哮喘患者中的:全国真实世界证据。
J Allergy Clin Immunol. 2021 Aug;148(2):361-367.e13. doi: 10.1016/j.jaci.2021.06.006. Epub 2021 Jun 15.
8
Therapeutic Application of Corticosteroids in COVID-19: A Focus on Optimum Dose and Duration of Therapy.皮质类固醇在COVID-19中的治疗应用:聚焦最佳治疗剂量和疗程
J Clin Pharmacol. 2021 Sep;61(9):1145-1148. doi: 10.1002/jcph.1929. Epub 2021 Jul 10.
9
Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia.精准皮质类固醇治疗对重症2019新型冠状病毒肺炎的潜在益处。
Signal Transduct Target Ther. 2020 Feb 21;5(1):18. doi: 10.1038/s41392-020-0127-9.
10
Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019.皮质类固醇在病毒性肺炎中的应用:迄今为止的经验和新冠肺炎中的地塞米松突破。
J Comp Eff Res. 2020 Dec;9(18):1247-1254. doi: 10.2217/cer-2020-0146. Epub 2020 Nov 27.

静脉注射皮质类固醇冲击是否优于小剂量皮质类固醇治疗重症 COVID-19 患者?

Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?

机构信息

BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil

BRICNet - Brazilian Research in Intensive Care Network, Brazil.

出版信息

Eur Respir J. 2022 Oct 20;60(4). doi: 10.1183/13993003.01220-2022. Print 2022 Oct.

DOI:10.1183/13993003.01220-2022
PMID:35777764
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9248174/
Abstract

Corticosteroids were the first drugs proven to reduce mortality in Covid-19. In June 2020, the RECOVERY group announced the results of their seminal trial showing dexamethasone 6 mg per day was able to reduce 28-day mortality in hospitalized patients with Covid needing supplemental oxygen or mechanical ventilation [1]. Meta-analysis from randomized controlled trials (RCT) in Covid-19 patients confirmed RECOVERY results [2]. In those RCTs, corticosteroid doses were low (dexamethasone 6 mg per day) or intermediate (dexamethasone up to 20mg per day).

摘要

皮质类固醇是第一批被证明能降低新冠死亡率的药物。2020 年 6 月,RECOVERY 研究组公布了他们的重要试验结果,表明每天给予 6mg 地塞米松可降低需要补充氧气或机械通气的住院新冠患者 28 天死亡率[1]。针对新冠患者的随机对照试验(RCT)的荟萃分析证实了 RECOVERY 研究的结果[2]。在这些 RCT 中,皮质类固醇的剂量较低(地塞米松每天 6mg)或中等(地塞米松每天高达 20mg)。